Man lives for 100 days with artificial titanium heart in successful new trial
The patient, a man in his 40s who declined to be identified, received the implant during surgery at St. Vincent's Hospital Sydney last November.
In February, he became the first person worldwide to leave hospital with the device, which kept him alive until a heart donor became available earlier this month.
According to a statement issued Wednesday by St Vincent's Hospital, Monash University and BiVACOR, the US-Australian company behind the device, the man, who had severe heart failure, was 'recovering well.'
The ability of the device to sustain him for so long is being celebrated as a sign the artificial heart could potentially offer a long-term option for people suffering heart failure. The device is still being trialed and has not yet been approved for general use.
BiVACOR's founder, Australian bioengineer Daniel Timms, who invented the device following his father's death from heart disease, said it was 'exhilarating to see decades of work come to fruition.'
'The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart,' he said in the statement. 'Their bravery will pave the way for countless more patients to receive this lifesaving technology.'
The BiVACOR Total Artificial Heart (TAH) has a single moving part, a levitated rotor that's held in place by magnets. As the name suggests, it's constructed from titanium and there are no valves or mechanical bearings that may be susceptible to wear.
It pumps blood to the body and the lungs, replacing both ventricles of a failing heart.
Cardiovascular diseases are the leading cause of death globally killing around 18 million people each year, according to the World Health Organization.
The long-term ambition is to use the device to save more people who languish on waiting lists for suitable donors. According to the US Health Department, about 3,500 people received heart transplants in 2024. Around 4,400 joined the waiting list the same year.
Professor Chris Hayward, from the Victor Chang Cardiac Research Institute, said the BiVACOR heart ushered in 'a whole new ball game for heart transplants.'
'Within the next decade we will see the artificial heart becoming the alternative for patients who are unable to wait for a donor heart or when a donor heart is simply not available,' said Hayward, who is overseeing the Australian patient's recovery and was involved in preparing the device for clinical trials.
The device has already been tested in the Food and Drug Administration's Early Feasibility Study in the United States, which saw five patients successfully implanted with the device.
The first was last July, when a 58-year-old man suffering end-stage heart failure received the implant during surgery at Texas Medical Center. It kept him alive for eight days until a donor was available.
Four other patients followed in the study, which examined the safety and performance of the device, while they waited for a donor transplant. It's hoped the trial will expand to 15 patients.
The Australian implant was the first in a series planned by Monash University's Artificial Heart Frontiers Program, a 50 million Australian dollar ($31 million) program to develop and commercialize three devices to treat heart failure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
'Frankenbunnies' with spikes on heads scaring Americans
These frightening rabbits have people hopping for cover in the U.S. A rapidly spreading virus is causing cottontail rabbits to grow black, tentacle-like growths out of their heads, prompting warnings to stay away from the mutated animals. The creatures, dubbed 'Frankenbunnnies,' have been seen multiple times in Fort Collins, Colo., per the New York Post. 'I thought he would die off during the winter, but he didn't,' resident Susan Manfield told 9News, per the Post, after she said she saw a rabbit with what looked like 'black quills or black toothpicks sticking out all around his or her mouth.' However, she said, 'he came back a second year, and it grew.' Another person described the infected rabbits as having a 'scabbiesh-looking growth over their face.' The bunny problem is caused by cottontail papilloma virus (CRPV), which is also known as Shope papilloma virus. It causes cottontails to sprout tumors around their head and is spread by parasites, ticks and fleas, which pass on the ailment through their bites, according to Pet MD. 'Typically, rabbits become infected in the warmer months of summer when transmitted by being bitten by insects like fleas and ticks,' Colorado Parks and Wildlife spokesperson Kara Van Hoose said, per the Coloradoan. Recommended video Recent sightings have occurred in Colorado but the disease most frequently comes up in the Midwest. With rampant CRPV sightings, wildlife experts are warning people not to approach or handle any of the afflicted rabbits. While the virus can spread between rabbits, it's not known to infect humans or pets. As such it is not considered a threat to public health, according to the Colorado Parks and Wildlife. According to the U.K. Daily Mail, the protrusions can grow to the point where they interfere with the infected rabbit's ability to eat, causing the animals to die of starvation. The disease is more severe in domestic bunnies than their wild brethren. CRPV has no known cure. Texas man wearing pacifier asked girls for 'diaper change': Cops Passenger's horrific diarrhea gets flight cancelled: 'I'M SO SORRY'
Yahoo
5 hours ago
- Yahoo
The US May Have Already Lost the AI Race to China Due to a Key Weakness
You might have heard of an "AI race" heating up between the US and China, a bitter rivalry between two global adversaries that could shape the direction of world history. At least, that's how some in the US feel. While China has repeatedly tried to establish a geopolitical friendship with the richest nation in the world, officials and pundits in the US have doubled down, reframing artificial intelligence as the 21st century's nuclear bomb. In the meantime, China may have gotten a massive lead — by actively investing in its power grid, while the United States' is quickly running out of capacity to power immensely power-hungry AI models. As Fortune reports, Americans who've had a look at China's technological development firsthand found that the two country's aren't even in the same league, given China's next-level power grid. "Energy is considered a solved problem," wrote Rui Ma, editor of the US publication Tech Buzz China. "Everywhere we went, people treated energy availability as a given," she continued. "This is a stark contrast to the US, where AI growth is increasingly tied to debates over data center power consumption and grid limitations." AI is a notoriously energy-intensive technology. The data centers powering large language models like ChatGPT are immense labyrinths of computer chips, which suck down resources like power and water in order to keep up with demand. As Fortune notes, this effectively makes electricity the key bottleneck for expanding AI infrastructure. That's caused some critical shortages in the US. Short on energy and hopped up on fantasies of an arms race, American companies are resorting to all kinds of bizarre strategies to get their juice. Elon Musk's xAI, for example, is running 35 portable methane gas generators in the parking lot of one of its main datacenters in Memphis, encircling nearby communities in a cloud of noxious smog. China has no such problems. In 2024, China was responsible for nearly 65 percent of the world's renewable energy construction, installing so many solar panels and wind turbines that it caused the country's CO2 emissions to drop for the first time — despite record-high demands for energy. Whether or not the US can catch up remains to be seen. President Donald Trump previously made an off-the-cuff remark about attaching coal power plants to data centers directly. It's an unfortunate conundrum in an age when energy demand in the US has never been higher. In the meantime, China keeps chugging along, seemingly unperturbed by any energy bottlenecks — and the Trump administration's posturing. More on AI: AI Datacenters Are Raising Nearby Residents' Electric Bills Solve the daily Crossword
Yahoo
5 hours ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
